Disrupted glucocorticoid-Immune interactions during stress response in schizophrenia

Psychoneuroendocrinology

Volumn 63, Issue , 2016, Pages 86-93

  Chiappelli, Joshua ^a   Shi, Qiaoyun ^a   Kodi, Priyadurga ^a   Savransky, Anya ^a   Kochunov, Peter ^a   Rowland, Laura M ^a   Nugent, Katie L ^a   Hong, L Elliot ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cortisol; IL 6; Inflammation; Schizophrenia; Stress

Indexed keywords

HYDROCORTISONE; INTERLEUKIN 6; GLUCOCORTICOID; IL6 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DOWN REGULATION; FEMALE; HORMONE RESPONSE; HUMAN; MALE; MENTAL STRESS; PRIORITY JOURNAL; SALIVA ANALYSIS; SCHIZOPHRENIA; TREND STUDY; CASE CONTROL STUDY; CHEMISTRY; COGNITION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PSYCHOLOGY; PSYCHOTIC DISORDERS; SALIVA; SHORT TERM MEMORY; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COGNITION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; PSYCHOTIC DISORDERS; SALIVA; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84949844546     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.09.010     Document Type: Article

References (67)

1. Andreassen O.A., Harbo H.F., Wang Y., Thompson W.K., Schork A.J., Mattingsdal M., Zuber V., Bettella F., Ripke S., Kelsoe J.R., Kendler K.S., O'Donovan M.C., Sklar P., The Psychiatric Genomics Consortium (PGC) Bipolar Disorder and Schizophrenia Work Groups, The International Multiple Sclerosis Genetics Consortium (IMSGC), McEvoy L.K., Desikan R.S., Lie B.A., Djurovic S., Dale A.M., The Psychiatric Genomics Consortium Bipolar Disorder and Schizophrenia Work Groups, The International Multiple Sclerosis Genetics Consortium IMSGC Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry 2015, 20:207-214.
2. Beards S., Gayer-Anderson C., Borges S., Dewey M.E., Fisher H.L., Morgan C. Life events and psychosis: a review and meta-analysis. Schizophr. Bull. 2013, 39:740-747.
3. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 2011, 168:1303-1310.
4. Bergink V., Gibney S.M., Drexhage H.A. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol. Psychiatry 2014, 75:324-331.
5. Brydon L., Walker C., Wawrzyniak A., Whitehead D., Okamura H., Yajima J., Tsuda A., Steptoe A. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav. Immun. 2009, 23:217-224.
6. Chiappelli J., Pocivavsek A., Nugent K.L., Notarangelo F.M., Kochunov P., Rowland L.M., Schwarcz R., Hong L.E. Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry 2014, 71:761-768.
7. Chrousos G.P. Stress and sex versus immunity and inflammation. Sci. Signal. 2010, 3:pe36.
8. Coutinho A.E., Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 2011, 335:2-13.
9. Da Silva J.A. Sex hormones and glucocorticoids: interactions with the immune system. Ann. N. Y. Acad. Sci. 1999, 876:102-117.
10. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76:135-157.
11. Dickinson D., Ragland J.D., Gold J.M., Gur R.C. General and specific cognitive deficits in schizophrenia: Goliath defeats David?. Biol. Psychiatry 2008, 64:823-827.
12. Docherty N.M., St Hilaire A., Aakre J.M., Seghers J.P. Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia. Schizophr. Bull. 2009, 35:638-645.
13. Dorn L.D., Lucke J.F., Loucks T.L., Berga S.L. Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann. Clin. Biochem. 2007, 44:281-284.
14. Duma D., Collins J.B., Chou J.W., Cidlowski J.A. Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci. Signal. 2010, 3:ra74.
15. Eaton W.W., Byrne M., Ewald H., Mors O., Chen C.Y., Agerbo E., Mortensen P.B. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 2006, 163:521-528.
16. Fineberg A.M., Ellman L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 2013, 73:951-966.
17. Forbes N.F., Carrick L.A., McIntosh A.M., Lawrie S.M. Working memory in schizophrenia: a meta-analysis. Psychol. Med. 2009, 39:889-905.
18. Frydecka D., Misiak B., Pawlak-Adamska E., Karabon L., Tomkiewicz A., Sedlaczek P., Kiejna A., Beszłej J.A. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur. Arch. Psychiatry Clin. Neurosci. 2015, 265:449-459.
19. Goodin B.R., Quinn N.B., King C.D., Page G.G., Haythornthwaite J.A., Edwards R.R., Stapleton L., McGuire L. Salivary cortisol and soluble tumor necrosis factor-α receptor II responses to multiple experimental modalities of acute pain. Psychophysiology 2012, 49:118-127.
20. Gunduz-Bruce H., Szeszko P.R., Gueorguieva R., Ashtari M., Robinson D.G., Kane J.M., Bilder R.M. Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophr. Res. 2007, 94:281-287.
21. Izawa S., Sugaya N., Kimura K., Ogawa N., Yamada K.C., Shirotsuki K., Mikami I., Hirata K., Nagano Y., Nomura S. An increase in salivary interleukin-6 level following acute psychosocial stress and its biological correlates in healthy young adults. Biol. Psychol. 2013, 94:249-254.
22. John C.D., Buckingham J.C. Cytokines: regulation of the hypothalamo-pituitary-adrenocortical axis. Curr. Opin. Pharmacol. 2003, 3:78-84.
23. Johnson J.D., O'Connor K.A., Deak T., Stark M., Watkins L.R., Maier S.F. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav. Immun. 2002, 16:461-476.
24. Johnson J.D., O'Connor K.A., Deak T., Spencer R.L., Watkins L.R., Maier S.F. Prior stressor exposure primes the HPA axis. Psychoneuroendocrinology 2002, 27:353-365.
25. Karanikas E., Antoniadis D., Garyfallos G.D. The role of cortisol in first episode of psychosis: a systematic review. Curr. Psychiatry Rep. 2014, 16:503.
26. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68:283-297.
27. Keefe R.S., Harvey P.D., Goldberg T.E., Gold J.M., Walker T.M., Kennel C., Hawkins K. Norms and standardization of the brief assessment of cognition in schizophrenia (BACS). Schizophr. Res. 2008, 102:108-115.
28. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992, 258:593-597.
29. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Köhler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
30. Kudoh A., Sakai T., Ishihara H., Matsuki A. Plasma cytokine response to surgical stress in schizophrenic patients. Clin. Exp. Immunol. 2001, 125:89-93.
31. Kunz-Ebrecht S.R., Mohamed-Ali V., Feldman P.J., Kirschbaum C., Steptoe A. Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines. Brain Behav. Immun. 2003, 17:373-383.
32. LeMay L.G., Vander A.J., Kluger M.J. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol. Behav. 1990, 47:957-961.
33. Lejuez C., Kahler C.W., Brown R.A. A modified computer version of the paced auditory serial addition task (PASAT) as a laboratory based stressor. Behav. Ther. 2003, 26:290-293.
34. Lyson K., McCann S.M. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology 1991, 54:262-266.
35. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr. Res 1995, 29:141-152.
36. Mastorakos G., Chrousos G.P., Weber J.S. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 1993, 77:1690-1694.
37. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
38. Mondelli V., Dazzan P., Hepgul N., Di F., orti M., Aas M., D'Albenzio A., Di N., icola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
39. Myin-Germeys I., van Os J. Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clin. Psychol. Rev. 2007, 27:409-424.
40. Myin-Germeys I., van Os J., Schwartz J.E., Stone A.A., Delespaul P.A. Emotional reactivity to daily life stress in psychosis. Arch. Gen. Psychiatry 2001, 58:1137-1144.
41. Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium, International Inflammatory Bowel Disease Genetics Consortium (IIBDGC), International Inflammatory Bowel Disease Genetics Consortium IIBDGC Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 2015, 18:199-209.
42. Noto C., Ota V.K., Gouvea E.S., Rizzo L.B., Spindola L.M., Honda P.H., Cordeiro Q., Belangero S.I., Bressan R.A., Gadelha A., Maes M., Brietzke E. Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. Int. J. Neuropsychopharmacol. 2015, 18:pyu042.
43. Nugent K.L., Chiappelli J., Rowland L.M., Daughters S.B., Hong L.E. Distress intolerance and clinical functioning in persons with schizophrenia. Psychiatry Res. 2014, 220:31-36.
44. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
45. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
46. Ray A., Prefontaine K.E. Physical association and functional antagonism between the ~65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:752-756.
47. Rhen T., Cidlowski J.A. Anti-inflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
48. Rohleder N. Acute and chronic stress induced changes in sensitivity of peripheral inflammatory pathways to the signals of multiple stress systems-2011Curt Richter Award Winner. Psychoneuroendocrinology 2012, 37:307-316.
49. Ryan M., Sharifi N., Condren R., Thakore J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004, 29:1065-1070.
50. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
51. Sehgal P.B. Regulation of IL6 gene expression. In: 46th Forum in Immunology. Res. Immunol. 1992, 143:724-734.
52. Silverman M.N., Sternberg E.M. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann. N. Y. Acad. Sci. 2012, 1261:55-63.
53. Sjögren E., Leanderson P., Kristenson M., Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav. Immun. 2006, 20:270-278.
54. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietiläinen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Børglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Böttcher Y., Olesen J., Breuer R., Möller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Réthelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Genetic Risk, Outcome in Psychosis (GROUP), Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de Frutos R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jönsson E.G., Terenius L., Agartz I., Petursson H., Nöthen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St Clair D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
55. Steinke J.W., Borish L. Cytokines and chemokines. J. Allergy Clin. Immunol. 2006, 117:S441-S445.
56. Steptoe A., Hamer M., Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun. 2007, 21:901-912.
57. Stojanovic A., Martorell L., Montalvo I., Ortega L., Monseny R., Vilella E., Labad J. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology 2014, 41:23-32.
58. Strong, D., Lejuez, C., Daughters, S., Marinello, M., Kahler, C., Brown, R., 2003. The computerized mirror tracing task version 1. Unpublished manual.
59. Tessner K.D., Mittal V., Walker E.F. Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders. Schizophr. Bull. 2011, 37:432-441.
60. Upthegrove R., Manzanares-Teson N., Barnes N.M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 2014, 155:101-108.
61. van Os J., Selten J. Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of the Netherlands. Br. J. Psychiatry 1998, 172:324-326.
62. van Venrooij J.A., Fluitman S.B., Lijmer J.G., Kavelaars A., Heijnen C.J., Westenberg H.G., Kahn R.S., Gispen-de Wied C.C. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr. Bull. 2012, 38:272-279.
63. van Winkel R., Stefanis N.C., Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr. Bull. 2008, 34:1095-1105.
64. Varese F., Smeets F., Drukker M., Lieverse R., Lataster T., Viechtbauer W., Read J., van O., S.J., Bentall R.P. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr. Bull. 2012, 38:661-671.
65. Wechsler D. Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) 1997, Harcourt Assessment, San Antonio, TX.
66. Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 2014, 141:125-139.
67. Zhou D., Kusnecov A.W., Shurin M.R., DePaoli M., Rabin B.S. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 1993, 133:2523-2530.